Hoth Therapeutics, Inc.
HOTH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,249 | $3,480 | $4,931 | $7,529 |
| G&A Expenses | $4,966 | $4,212 | $6,134 | $6,572 |
| SG&A Expenses | $4,966 | $4,212 | $6,134 | $6,572 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8,215 | $7,692 | $11,066 | $14,101 |
| Operating Income | -$8,215 | -$7,692 | -$11,066 | -$14,101 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $27 | -$153 | -$306 | -$212 |
| Pre-Tax Income | -$8,188 | -$7,845 | -$11,372 | -$14,314 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,188 | -$7,845 | -$11,372 | -$14,314 |
| % Margin | – | – | – | – |
| EPS | -1.28 | -2.3 | -9.5 | -16.03 |
| % Growth | 44.3% | 75.8% | 40.7% | – |
| EPS Diluted | -1.28 | -2.3 | -9.5 | -16.03 |
| Weighted Avg Shares Out | 6,375 | 3,409 | 1,198 | 893 |
| Weighted Avg Shares Out Dil | 6,375 | 3,409 | 1,198 | 893 |
| Supplemental Information | – | – | – | – |
| Interest Income | $28 | $52 | $6 | $0 |
| Interest Expense | $0 | $0 | $305 | $0 |
| Depreciation & Amortization | $8,215 | $7,692 | $11,066 | $0 |
| EBITDA | $27 | -$153 | $0 | -$14,101 |
| % Margin | – | – | – | – |